REDUÇÃO DE MORTALIDADE POR COVID-19 NOS PACIENTES QUE JÁ SÃO USUÁRIOS DE IECA E/OU BRA

Abstract

In late 2019, coming from a fish and wildlife market in China, COVID-19 quickly caused a major global outbreak, becoming a major public health problem, then considered a new pandemic. This disease is characterized by an infectious phase where flu-like symptoms predominate, evolving into a phase of respiratory distress and then a hyperinflammatory condition, which usually has worse outcomes. For this, SARS-CoV-2 uses ACE2 as a gateway to the cells where it replicates. However, this enzyme has an important regulatory function of SARS, which in abnormal situations generates deleterious effects on several systems. Therefore, the fact that SRA inhibitor drugs can positively regulate the expression of ACE2 generated inquiries about its possible therapeutic benefit during COVID-19. For the execution of this work an integrative literature review was adopted, using the PubMed and SciELO databases, as well as DeCS and MeSH in English (COVID-19, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Type 1 Receptor Blockers, and Mortality) and their correspondents in Portuguese and Spanish, combined with the Boolean operator "AND". Given the above, it has become imperative that the scientific community accumulate clinical data to determine whether there is a link between the use of ACE inhibitors, ARBs, or both, and disease mortality and morbidity. Until more substantial data are available to guide more accurate decision-making.